SYS6002 versus chemotherapy for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called SYS6002 against standard chemotherapy for patients with advanced bladder cancer (urothelial carcinoma) that has already progressed despite previous treatments. The goal is to see if SYS6002 works better and is safer than chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Bladder cancer that is locally advanced or has spread to other parts of the body (metastatic)
- Previous treatment with platinum-based chemotherapy and immunotherapy (PD-L1 inhibitors) that did not work or stopped working
- Measurable tumors visible on imaging scans
- Good overall health status (able to care for yourself with minimal help)
- At least 3 months life expectancy and normal organ function (blood, kidneys, liver, clotting)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial is testing a new combination of two drugs (9MW2821 and toripalimab) against standard chemotherapy for people with advanced bladder cancer that has not been treated before. The goal is to see if this new approach works better at shrinking tumors or slowing the cancer's growth.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
This trial tests a new drug called SYS6002 against standard chemotherapy for cervical cancer that has come back or spread. It aims to see if SYS6002 works better for people who have already tried platinum chemo and immunotherapy.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.